IL33 and arthritic joint disease: Taken together, all of the concepts expressed herein demonstrate that IL-33 (“alarmin”) can exacerbate inflammatory allergic skin reaction and increase TH1 response—as occurs in experimental arthritis induced in mice—but also that IL-33 is capable of inhibiting proinflammatory IL-18 released by macrophages, demonstrating anti-inflammatory activity.